Eli Lilly and Company (LLY) Stock Analysis
Is LLY a good investment?
Eli Lilly and Company (LLY) has a Plutrex AI rating of 85.0/100 as of August 19, 2026, indicating a Strong Buy consensus. The stock is halal-compliant per AAOIFI standards. Key strength: PEG ratio of 0.87 vs. industry average 1.72 — 49.4% growth-adjusted discount to peers despite 26.1% P/E premium (41.65x vs. 33.04x). LLY's 5-year EPS CAGR of 30.3% is 270.9% above the industry average of 8.2%, making it mathematically cheaper per unit of growth than virtually every peer. This is the single most powerful valuation signal and the primary reason to own the stock.. Main concern: Valuation compression risk: At $1,226.67 with analyst consensus $1,345.81, near-term upside is only 9.7% — modest for a stock with a 41.65x P/E. Revenue growth decelerated from 55.5% to 47.7% (-14.1% rate of change) — still exceptional but continued deceleration could pressure the multiple. If 5-year EPS growth of 30.3% disappoints even modestly (e.g., delivers 22-25%), the P/E multiple would need to compress significantly, creating meaningful downside from current levels. The stock has appreciated 2.8% from the prior-prior report ($1,192.80 → $1,226.67), further narrowing the risk/reward..
Investment Summary
Eli Lilly (LLY) at $1,226.67 remains one of the highest-conviction large-cap growth opportunities in the pharmaceutical sector. The investment thesis is anchored by a PEG ratio of 0.87 — 49.4% below the industry average of 1.72 — meaning investors are acquiring LLY's 30.3% five-year EPS growth at a significant discount to peers despite a headline P/E of 41.65x. Profitability is world-class: gross margin 83.4%, operating margin 54.2% (80.7% above peers), net margin 33.5% (126.1% above peers), and FCF of $11.065B annually. Revenue grew 47.7% YoY — more than 6x the industry average of 7.5%. The analyst consensus target of $1,345.81 implies 9.7% upside from current price. News sentiment is exceptionally strong at 94.6/100 (10 positive, 0 negative), with headlines confirming GLP-1 market expansion ('Eli Lilly Just Scored a European Weight Loss Pill Approval'), competitive differentiation ('Eli Lilly Is Building a Weight Loss Drug for Every Kind of Patient'), and pricing power reframing ('Eli Lilly's GLP-1 Pricing Problem Is Actually a Growth Opportunity'). The stock is up only 0.5% from the prior report ($1,220.51 → $1,226.67), with no material metric changes — the thesis is fully intact. Primary risk remains valuation compression if 30.3% EPS growth disappoints, and competitive pressure from Novo Nordisk and emerging GLP-1 entrants.
Key Strengths
- PEG ratio of 0.87 vs. industry average 1.72 — 49.4% growth-adjusted discount to peers despite 26.1% P/E premium (41.65x vs. 33.04x). LLY's 5-year EPS CAGR of 30.3% is 270.9% above the industry average of 8.2%, making it mathematically cheaper per unit of growth than virtually every peer. This is the single most powerful valuation signal and the primary reason to own the stock.
- Best-in-class profitability moat with operating margin 54.2% (80.7% above peers), net margin 33.5% (126.1% above peers), gross margin 83.4% (20.9% above peers), and FCF of $11.065B annually. Revenue growth of 47.7% YoY (539% above industry average of 7.5%) confirms the top-line engine is firing. European oral GLP-1 pill approval (Foundayo) opens a new geographic growth vector, and 'Eli Lilly Is Building a Weight Loss Drug for Every Kind of Patient' confirms multi-product pipeline depth extending the runway.
- News sentiment 94.6/100 with 10 positive, 0 negative headlines. 'Eli Lilly's GLP-1 Pricing Problem Is Actually a Growth Opportunity' reframes the pricing narrative positively — pricing differentiation among obesity treatments is a feature, not a bug, per Novo CEO commentary. 'Eli Lilly Stock Nears Buy Point After Earnings-Fueled Gains' confirms technical momentum post-Q2 2026 results. The global GLP-1 market forecast for rapid expansion provides multi-year structural tailwind.
Key Concerns
- Valuation compression risk: At $1,226.67 with analyst consensus $1,345.81, near-term upside is only 9.7% — modest for a stock with a 41.65x P/E. Revenue growth decelerated from 55.5% to 47.7% (-14.1% rate of change) — still exceptional but continued deceleration could pressure the multiple. If 5-year EPS growth of 30.3% disappoints even modestly (e.g., delivers 22-25%), the P/E multiple would need to compress significantly, creating meaningful downside from current levels. The stock has appreciated 2.8% from the prior-prior report ($1,192.80 → $1,226.67), further narrowing the risk/reward.
- Structural competitive pressure from Novo Nordisk's semaglutide franchise and emerging GLP-1 entrants (Amgen, Viking Therapeutics). While Novo CEO commentary that 'investors are underestimating demand for differentiation' is net positive for LLY (suggesting the market is large enough for multiple winners), it also confirms that competitive intensity is real and growing. IP enforcement actions and litigation remain ongoing risks. The D/E ratio of 1.41, while below the industry average of 1.78, still introduces financial leverage risk if revenue growth decelerates materially.
Plutrex 10-Factor AI Breakdown
Fundamental Analysis
LLY's fundamentals are categorically superior across profitability, growth, and growth-adjusted valuation. Profitability: Gross margin 83.4% vs. industry 68.9% (+20.9%), operating margin 54.2% vs. industry 30.0% (+80.7%), net margin 33.5% vs. industry 14.8% (+126.1%), ROE 102.4% (partially leveraged by D/E of 1.41). FCF of $11.065B provides exceptional capital allocation flexibility. Growth: Revenue growth 47.7% YoY vs. industry 7.5% (+539%), 5-year forward EPS CAGR 30.3% vs. industry 8.2% (+270.9%), next-year EPS growth 28.3%. Valuation: P/E 41.65x vs. industry 33.04x (+26.1% premium), but PEG 0.87 vs. industry 1.72 (-49.4% discount) — the dominant signal. Price-to-book 34.06x is elevated but reflects intangible pharmaceutical asset value not captured on balance sheet. Financial health is the weakest dimension: D/E 1.41 (vs. industry 1.78 — actually 20.8% below peers), cash $8.95B, FCF $11.065B. The gap between operating margin (54.2%) and net margin (33.5%) reflects meaningful interest expense from the debt load. Analyst consensus target $1,345.81 implies 9.7% upside. Intrinsic value assessment: at PEG=1.0 fair value, the stock is modestly undervalued; at PEG=1.2 quality-adjusted, it is fairly valued. The 5-year DCF at 30.3% growth decelerating to 10% terminal, discounted at 10%, supports a P/E range of 35-45x — current 41.65x sits near midpoint of fair value.
News Sentiment
Eli Lilly is riding one of the most powerful waves in pharmaceutical history — and the latest headlines suggest the ride is far from over. The company's blockbuster weight loss and diabetes drugs are reshaping medicine, and Wall Street is taking notice. The biggest recent development: Eli Lilly just scored Europe's first approval for an oral weight loss pill, Foundayo — a landmark moment that opens an entirely new market for the company. As one headline put it, 'Eli Lilly Just Scored a European Weight Loss Pill Approval — and the Growth Story Continues.' For millions of patients who prefer pills over injections, this could be a game-changer. Back home, the company's Q2 2026 earnings sent the stock surging, with 'Eli Lilly Stock Nears Buy Point After Earnings-Fueled Gains' capturing the momentum. Investors are watching closely how quickly new products are gaining traction with patients and doctors. There's also a fascinating narrative shift happening around pricing. A headline declaring 'Eli Lilly's GLP-1 Pricing Problem Is Actually a Growth Opportunity' reflects growing recognition that having multiple drugs at different price points isn't a weakness — it's a strategy. Even Novo Nordisk's CEO has acknowledged that investors are underestimating how much patients want choices in obesity treatment, which actually benefits Lilly. The big picture: the global GLP-1 drug market is forecast to explode in the coming years, and Lilly is positioning itself to serve 'every kind of patient' — from those who want pills to those who need injections. For everyday investors, the story is simple: Lilly is building a weight loss empire, and it's just getting started.
Risk Assessment
PRIMARY RISK: Valuation compression if 30.3% five-year EPS growth trajectory disappoints. At P/E 41.65x, every 5 percentage points of growth shortfall could compress the multiple by 5-8x, implying 12-20% downside from current levels. MITIGATION: PEG of 0.87 provides a growth-adjusted buffer; even at 25% EPS growth, LLY would still trade at a PEG below 1.0 at current prices. SECONDARY RISK: Competitive entry from Novo Nordisk (Ozempic/Wegovy), Amgen (MariTide), and Viking Therapeutics could compress GLP-1 pricing and market share, threatening the revenue growth rate that underpins the 30.3% EPS CAGR. MITIGATION: LLY's multi-product strategy ('Building a Weight Loss Drug for Every Kind of Patient'), European oral pill approval (Foundayo), and active IP enforcement create meaningful competitive moats. TERTIARY RISK: Financial leverage (D/E 1.41) amplifies downside if revenue growth decelerates — interest expense already compresses net margin from 54.2% operating to 33.5% net. MITIGATION: $11.065B FCF and $8.95B cash provide substantial debt serviceability. Stop-loss at $1,095 (10.7% below entry midpoint of $1,207.50) limits downside to a defined level while allowing normal volatility.
Related Halal Stocks
Related Stocks
Frequently Asked Questions
Is LLY a halal stock?
Yes, Eli Lilly and Company (LLY) is halal-compliant per AAOIFI standards as of the latest quarterly review.
What is Plutrex's AI rating for LLY?
Eli Lilly and Company (LLY) has a Plutrex AI rating of 85.0/100 with a Strong Buy consensus, based on a 10-factor analysis covering financial health, growth, valuation, profitability, debt, analyst sentiment, technical momentum, insider confidence, news sentiment, and halal compliance.
Is LLY a good investment?
According to Plutrex AI, LLY has a Strong Buy rating (85.0/100). For the full analysis including trading plan and risk assessment, see the detailed breakdown above.
How can I invest in LLY?
US stocks like LLY can be bought through international brokers such as Interactive Brokers, accessible to Arab investors. Plutrex provides comprehensive analysis plus AI-generated trading plans with entry points, stop losses, and profit targets.
What are the main risks of investing in LLY?
Plutrex AI identifies the main risks for LLY by analyzing valuation, debt, market sentiment, and macro factors. See the Risk Assessment section above for the full breakdown.